FDA pooled analysis of time to treatment discontinuation (TTD) in frontline advanced renal cell carcinoma trials.
2020
5081Background: Time to treatment discontinuation (TTD) has been proposed as a potential pragmatic real-world data (RWD) endpoint, and was closely correlated with progression-free survival (PFS) in...
Keywords:
-
Correction
-
Source
-
Cite
-
Save
0
References
0
Citations
NaN
KQI